The current status of stent placement in small coronary arteries < 3.0 mm in diameter
- PMID: 15282416
The current status of stent placement in small coronary arteries < 3.0 mm in diameter
Abstract
Data accrued to date indicate that stent placement in small vessels (< 3.0 mm reference diameter) suffers from the same disadvantage as other non-stent interventional devices in that the restenosis rate is significantly higher than observed following intervention involving large vessels. Randomized trials comparing systematic bare metal stenting versus conventional balloon angioplasty in the setting of small coronary arteries, however, show that the former therapeutic modality is probably superior to the latter treatment in its acute and mid-term angiographic and clinical results. Balloon angioplasty, even if performed optimally with resultant stent-like luminal outcome, yields a restenosis rate that is at best equivalent to that observed with stent placement. Stent performance is influenced profoundly by stent design and configuration. Tubular and corrugated stents are better than coil or meshwire stent design. Stents with thin struts appear to yield a lower restenosis rate compared with thick-strut stents. Coating the surface of stents with gold, phosphorylcholine or heparin does not appear to confer any additional long-term benefit compared with bare stainless-steel stents. On the other hand, impregnation of stents with anti-proliferative drugs, with or without a carrier polymer, has produced a significantly lower risk of restenosis, without an increase in stent thrombosis rate, compared with uncoated metal stents in multiple randomized trials. However, whether the clinico-anatomic benefits of drug-eluting stents can be sustained for several years and whether there are any long-term deleterious effects from the antiproliferative drug or carrier polymer remains unclear at this stage.
Comment in
-
Contemporary treatment of small-vessel disease.J Invasive Cardiol. 2004 Aug;16(8):417-8. J Invasive Cardiol. 2004. PMID: 15282417 No abstract available.
Similar articles
-
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.JAMA. 2005 Jan 12;293(2):165-71. doi: 10.1001/jama.293.2.165. JAMA. 2005. PMID: 15644543 Clinical Trial.
-
Drug-eluting stents.Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Arch Cardiol Mex. 2006. PMID: 17091802 Review.
-
A stent is not just a stent: Stent construction and design do matter in its clinical performance.Singapore Med J. 2004 Jul;45(7):305-11; quiz 312. Singapore Med J. 2004. PMID: 15221045 Review.
-
Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization.Catheter Cardiovasc Interv. 2007 May 1;69(6):790-8. doi: 10.1002/ccd.21011. Catheter Cardiovasc Interv. 2007. PMID: 17290437 Clinical Trial.
-
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial.J Am Coll Cardiol. 2007 Sep 18;50(12):1123-31. doi: 10.1016/j.jacc.2007.06.015. Epub 2007 Sep 4. J Am Coll Cardiol. 2007. PMID: 17868802 Clinical Trial.
Cited by
-
Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry.Catheter Cardiovasc Interv. 2014 Feb;83(2):192-200. doi: 10.1002/ccd.23194. Epub 2013 Oct 24. Catheter Cardiovasc Interv. 2014. PMID: 21735515 Free PMC article.
-
New stent design for use in small coronary arteries during percutaneous coronary intervention.Med Devices (Auckl). 2010;3:57-66. doi: 10.2147/MDER.S13494. Epub 2010 Oct 19. Med Devices (Auckl). 2010. PMID: 22915922 Free PMC article.